ESMO FAMILY SITES
Welcome to the European Society for Medical Oncology (ESMO), the leading European professional organization representing medical oncologists. more about ESMO ...
ESMO NEWS
- 18.12.08 - Announcing new Late-Breaking Abstract Policy: ECCO 15 – ESMO 34, Berlin, 20 – 24 September 2009
We are pleased to announce new and exciting developments that reflect our concerted efforts to...
- 15.12.08 - Cast your votes!
The online election process for the ESMO Nominating Committee is now open.
- 10.12.08 - Rare cancers are common; optimal care is not: ESMO calls for equal access to optimal care in rare cancers
The European Society for Medical Oncology (ESMO) hosted today a press briefing in the European...
- 09.12.08 - Professor Jan Vermorken is the new editor-in-chief of Annals of Oncology
Professor Jan B. Vermorken, an internationally respected medical oncologist based at Antwerp...
- 04.12.08 - ESMO announces new Executive Director
Alan Howard, who has managed professional medical organizations for more than 20 years, has been...
[more...]
ONCOLOGY NEWS
- 23.12.08 - Lapatinib significantly improves clinical efficacy of aromatase inhibitor in front-line postmenopausal hormone receptor positive metastatic breast cancer
First results from EGF30008 trial presented at San Antonio Breast Cancer Symposium
- 22.12.08 - Individual patient data meta-analysis on behalf of the EPO IPD meta-analysis collaborative group
Risks associated with recombinant human erythropoiesis-stimulating agents must be balanced against...
- 19.12.08 - TEAM pathology study is the only prospective analysis of interaction between progesterone receptor and efficacy of exemestane versus tamoxifen as initial adjuvant endocrine therapy
Progesterone receptor expression is prognostic but not predictive for differential response
- 18.12.08 - Progression-free survival and SPARC tumor correlatives from phase II neoadjuvant trial of gemcitabine, epirubicin, and nab paclitaxel
Patients with early relapse more likely to demonstrate triple negative phenotype, or estrogen- or...
- 12.12.08 - Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy may become new standard first-line therapy for treating advanced chronic lymphocytic leukemia
Results of phase III clinical trial presented at ASH Annual Meeting
[more...]
ESMO Nominating Committee
ESMO Congress
Young Oncologist Corner
ESMO Practice Tools